A 1999 investigation1 found that industry sponsorship of cost-effectiveness analyses (CEAs) for oncology drugs was associated with lower likelihood of reporting unfavorable conclusions relative to CEAs with other sponsorship. Over the past 15 years, the CEA literature for oncology drugs has expanded dramatically, and oncology now accounts for the largest single pharmaceutical sales area worldwide.2 We sought to determine whether the association between industry sponsorship and CEA results has persisted.
Lane JD, Friedberg MW, Bennett CL. Associations Between Industry Sponsorship and Results of Cost-effectiveness Analyses of Drugs Used in Breast Cancer Treatment. JAMA Oncol. 2016;2(2):274–276. doi:10.1001/jamaoncol.2015.3928